February 9, 2018 / 12:57 PM / 8 months ago

BRIEF-Catalyst Biosciences Announces Positive Top-Line Data From Phase 1/2 Study Of Subcutaneous Cb 2679D/Isu304

Feb 9 (Reuters) - Catalyst Biosciences Inc:

* CATALYST BIOSCIENCES ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 1/2 STUDY OF SUBCUTANEOUS CB 2679D/ISU304 IN INDIVIDUALS WITH HEMOPHILIA B

* CATALYST BIOSCIENCES INC - ALL INDIVIDUALS WITH SEVERE HEMOPHILIA IMPROVED TO MILD HEMOPHILIA ACTIVITY LEVELS AFTER ONLY SIX DAILY DOSES

* CATALYST BIOSCIENCES - ‍RESULTS SUGGEST LONG-TERM DOSING OF SQ CB 2679D COULD MAINTAIN STABLE CLOTTING ACTIVITY IN HIGH-MILD HEMOPHILIA TO NORMAL RANGE​

* CATALYST BIOSCIENCES INC - ‍NO INHIBITORS TO CB 2679D OR FIX WERE INDUCED TO DATE​

* CATALYST BIOSCIENCES-‍1 SUBJECT HAD MODERATE ADVERSE EVENTS OF PAIN,ERYTHEMA,REDNESS AFTER FIRST 2 INJECTIONS, MILD RATING AFTER SUBSEQUENT INJECTIONS​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below